Vaxcyte, Inc. — Director's Dealing 2022

Mar 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-03-02

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-02	Common Stock	A	6000	$0.00	Acquired	16629	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-02	Stock Option (right to buy)	$24.79	A	33000	Acquired	2032-03-01	Common Stock (33000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	341227	Indirect
Common Stock	50000	Indirect

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter.

F2: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter.